Trials / Completed
CompletedNCT04675242
Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension, 0.1% QD for the Treatment of Acute Exacerbations of Blepharitis (Mississippi)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 224 (actual)
- Sponsor
- Nicox Ophthalmics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of blepharitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NCX 4251 | NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily |
| DRUG | Placebo | Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily |
Timeline
- Start date
- 2020-12-14
- Primary completion
- 2021-06-16
- Completion
- 2021-06-30
- First posted
- 2020-12-19
- Last updated
- 2023-06-18
- Results posted
- 2022-12-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04675242. Inclusion in this directory is not an endorsement.